Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Florida for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Florida only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Florida (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Peter Bracha (NPI 1871908889)

Field	Value
Entity Type	Individual
Organization	Peter Bracha
Address	2329 Medico Ln Ste 103
City	Melbourne
State	FL
ZIP	32940
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	June 27, 2014

Payer Source	Total Paid
Medicare	$4M
Medicaid	$0

Key Findings

PETER BRACHA is a Retina Specialist (Ophthalmology) physician with an NPI enumerated 2014-06-27 (~12 years ago) whose lifetime Medicare revenue on file is $4M and who has no Medicaid billing on file. The dataset therefore represents an effectively single‑payer (Medicare‑dominated) billing profile rather than a mixed Medicare/Medicaid practice, which will shape payer contracting and population-risk considerations for analysts.

Revenue is highly concentrated in intravitreal biologic injections: the precomputed top‑3 Medicare codes (J2777, J0178, J2778) account for 87.5% of this provider's total Medicare revenue. Specifically, J2777 accounts for $2.2M (55.3%), J0178 accounts for $837.8K (21.0%), and J2778 accounts for $443.2K (11.1%), indicating the practice’s financial picture is dominated by anti‑VEGF and related ocular biologic therapy.

The code mix and descriptions indicate an operations model centered on high-volume intravitreal injection services and retina diagnostics. High volumes and revenues for injection codes (J2777, J0178, J2778) together with elevated counts for intravitreal procedure 67028 (2.3K claims, $197.3K, 5.0%) and retinal imaging 92134 (3K claims, $84.9K, 2.1%) suggest a clinic workflow built around frequent therapeutic injections with routine imaging and follow‑up visits.

On national competitive standing, this provider is an outlier for specific products: J2777 (faricimab) is exceptionally concentrated — $2.2M revenue (55.3%) and ranks #38 of 2039 providers nationally (98th percentile; extreme outlier), marking the clinician as a high‑volume national outlier for faricimab administration. Separately, 92134 ranks #390 of 26868 (99th percentile; extreme outlier), indicating unusually high retinal imaging volume relative to peers.

Other top injection codes show more typical national participation: J0178 (aflibercept) reports $837.8K (21.0%) and ranks #1077 of 3204 (66th percentile; typical, unremarkable volume), while J2778 (ranibizumab) reports $443.2K (11.1%) and ranks #155 of 1208 (87th percentile; typical, unremarkable volume). This pattern indicates strong specialization in certain new/brand biologics (faricimab) alongside more typical utilization of established agents.

Several procedure-level signals reflect a high case throughput and routine follow-up model: 67028 shows 2.3K claims and $197.3K (5.0%) and ranks #255 of 4255 (94th percentile; notably above typical national volume), while evaluation-and-management code 99213 shows 907 claims and $55.3K (1.4%) and ranks #8091 of 457151 (98th percentile; extreme outlier). Together these values imply frequent same‑day or stand‑alone intravitreal injection encounters supported by substantial E/M and imaging volumes.

From a payer strategy perspective, the practitioner’s extreme concentration in J2777 creates both a competitive advantage and exposure: the provider appears to be a national high‑volume administrator of faricimab (J2777), which could support negotiation leverage for drug access or site‑of‑service arrangements, but also means revenue is sensitive to shifts in utilization, supply, or reimbursement for that single product. Analysts should flag this concentration when modeling revenue risk or forecasting utilization changes tied to particular biologics.

The absence of any Medicaid billing on file ("none below") combined with $4M in Medicare revenue means this provider operates without an observable Medicaid footprint in the available data. That single‑payer orientation should be considered when assessing patient mix, access-to-care patterns, and revenue diversification opportunities; analysts seeking Medicaid exposure or state program risk should note there is no in‑state Medicaid activity reported.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

24 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2777	Injection, faricimab‑svoa, 0.1 mg	75,930	$30	$2.2M
J0178	Injection, aflibercept, 1 mg	1,220	$690	$837.8K
J2778	Injection, ranibizumab, 0.1 mg	2,480	$180	$443.2K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,290	$90	$197.3K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	3,030	$30	$84.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	910	$60	$55.3K
J3590	Unclassified biologics	280	$160	$43.4K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	180	$160	$27.8K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	250	$80	$21.3K
67042	In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina…	20	$810	$13.7K

Showing 1–10 of 24

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Florida Distribution

Peter Bracha — 4 of 24 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Florida

Full comparison — all codes billed, vs. state median

24 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	13	250	800	$690	$817.6K
J2777	8	170	12,810	$30	$549.2K
J2778	4	110	660	$180	$234.1K
67028	9	300	710	$90	$91.1K
J3590	9	20	30	$1,360	$50.3K
J7312	6	40	230	$160	$45.5K
67042	14	80	20	$1,180	$36.5K
92014	210	2,180	160	$80	$28.5K
67108	14	60	20	$1,200	$27.5K
99214	1,866	32,760	140	$90	$25K

Showing 1–10 of 24

Related Providers

Other providers that share a Tax Identification Number (TIN) with Peter Bracha, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ohiohealth Corporation	OH	Family Medicine Physician	$0	$89.1M
Gundersen Lutheran Medical Center Inc	WI	General Acute Care Hospital	$0	$74.3M
University Of Penn-medical Group	PA	Emergency Medicine Physician	$0	$21.5M
University Of Penn-medical Group	PA	Diagnostic Radiology Physician	$0	$17.7M
Mercy Health System Corporation	WI	Multi-Specialty Clinic/Center	$0	$13.2M
Gundersen Clinic Ltd	WI	Clinic/Center	$0	$10.1M
Imaging Subspecialists Of North Jersey, LLC	NJ	Diagnostic Radiology Physician	$0	$7.5M
Bruce Saran	PA	Ophthalmology Physician	$2.9M	$0
Frank Venzara	FL	Ophthalmology Physician	$2.5M	$0
University Of Penn-medical Group	PA	Clinical Medical Laboratory	$1.2M	$1.3M

Nearby Providers

Other providers in the same ZIP code as Peter Bracha, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Robert Johnson	FL	Adult Health Nurse Practitioner	$8.3M	$0
Ashish Dalal	FL	Medical Oncology Physician	$3M	$0
Amit Barochia	FL	Medical Oncology Physician	$2.4M	$0
Brendan Prendergast	FL	Radiation Oncology Physician	$1.5M	$0
Atlantic Surgery & Laser Center LLC	FL	Ambulatory Surgical Clinic/Center	$1.4M	$0
Sean Kearin	FL	Medical Oncology Physician	$1.1M	$0
Hong Jeong	FL	Interventional Cardiology Physician	$870.4K	$0
Jeannine Stein	FL	MOHS-Micrographic Surgery Physician	$737.1K	$0
Abraham Hardoon	FL	Internal Medicine Physician	$490.8K	$147.6K
Scott Hardoon	FL	Internal Medicine Physician	$578.1K	$0

Peter Bracha — Billing Profile & Reimbursement Data

Sign up for Peter Bracha — Billing Profile & Reimbursement Data policy alerts

Peter Bracha — Billing Profile & Reimbursement Data

Sign up for Peter Bracha — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References